TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Asynchronies Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NDI From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fecal microflora composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intestinal symptoms and well-being
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Novel score (Mosbah) score for evaluation of previous cesarean section scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood levels of SK&F-104557 and SK&F-89124
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence Rate of Laboratory-confirmed Symptomatic Dengue Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants Not Requiring Removal or Reoperation of the Implant
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of patients without Metabolic Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence rate of amifostine-associated hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Development of serious cardiovascular or cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brain activation during functional MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain connectivity during functional MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Confirmed diagnosis of polymyositis / dermatomyositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EGFR density in epidermis of psoriasis lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Complete Renal Response (CRR) at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Self-efficacy in symptom management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nerve Block Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine Equivalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of ABCB1 genetic polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of SLC22A16 genetic polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MACE at 30 Days
Endpoint domain: Mortality/survival
Primary endpoint: PDA closure after 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PDA closure after two weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Event-Free Survival Probability
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Childhood Autism Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Autism Treatment Evaluation Checklist
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Dose titration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue sodium content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progressive Tibial Radiolucencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving to Drink Alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Localization of Bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of psychological stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nausea Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Patency of the endoAVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Adherence in oral diabetes medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adherence in renin-angiotensin system antagonists (RASA) medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: saturation of oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical symptoms at 1-yr follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endothelial cell injury/inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Similarity of taste sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Basal body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory Complications Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: patterns and intensity of recipient alloreactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: recipient gene expression profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: polymorphic variants of specific susceptibility genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GERD-associated symptoms relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total AISRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychological resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression Anxiety and Stress Scale (DASS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Activated S6serine235
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of genital irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Essential Tremor Rating Scale (ETRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients Experiencing a Clinically Relevant Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of preparation (Ottawa score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acquisition of oral streptococcus mutans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Grade 2 or Higher Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving Vaccine Seroresponse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative incidence of complete molecular remissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Organ Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Cosmesis
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in mental health service utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 2-year relative survival
Endpoint domain: Mortality/survival
Primary endpoint: 2-year observed survival
Endpoint domain: Mortality/survival
Primary endpoint: Random urinary sodium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative Incidence of Severe Oral Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective tumor response rate (CR and PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total Interleukin-9 (IL-9) Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Treatment Related Morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients with Serious and Non-Serious Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Combined Circumference Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Product compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly phenylalanine control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dutch Periodontal Screening Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographically (X-OPT) calculated bone loss in millimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque index in percentages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pentraxin-3 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ferritin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time From Randomization to Virologic Failure or Death
Endpoint domain: Mortality/survival
Primary endpoint: Scores of symptom subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Participants' perception of the quality of the broadband connection
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Acute, Serious Bacterial Infections
Endpoint domain: Adverse events/effects
Primary endpoint: percent of improvement of quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bells test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of ASP8273 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ASP8273 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of ASP8273 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Compliance With Infection Prevention Practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Common side effects perceived by patients
Endpoint domain: Adverse events/effects
Primary endpoint: Increased stiffness of the carotid artery wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Raised neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Continent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Walking Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain-free Walking Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of required treatments to maintain serum ferritin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Interval between treatments per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target Vessel Failure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: occurrence of active tuberculosis
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Plasma PF-04965842 PK parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caloric intake in intubated ICU patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Likelihood of recommending program to a friend
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Normalization of arterial systolic hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk factors for gestational diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ground Contact Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in triglycerides (TG) and glucose responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) Graded By Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Simpson Angus Scale (SAS) Total Score at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to Discontinuation Due to AE
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in Average Nausea Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in GerdQ sum scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Inflammation of the Liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Complete Remission
Endpoint domain: Mortality/survival
Primary endpoint: COVID19 antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: COVID19 T cell immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Participant's Self-Assessment of Severity of Vaginal Dryness to Final Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Vaginal pH to Final Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Percentage of Vaginal Superficial Cells to Final Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Percentage of Vaginal Parabasal Cells to Final Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ventricular arrythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceptability of the Sentinel™ PCC4 Assay
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Performance characteristics of the Sentinel™ PCC4 Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Left Ventricular Mass Indexed to Height (LVMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total dose of sufentanil administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence of grade 3-5 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Conners' Continuous Performance Test II (CPT-II) Confidence Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional Lung Aeration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: frequency of headache days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Rate of diagnosis of portal hypertension (PH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of diagnosis of clinically significant portal hypertension (CSPH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean NeuroTracker Speed Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal NeuroTracker Speed Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NeuroTracker Speed Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with new lesions on T2-weighted images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: HIV testing engagement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of FT3, FT4, TSH, TPOAb levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: dryness of hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: dryness of feet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of preterm birth
Endpoint domain: Mortality/survival
Primary endpoint: Thromboelastography parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of patients with TTP with neurological complications at acute presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients with TTP in remission with long-term neurological complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Negativization of the exercise challenge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of suicidal ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maternal HIV Incidence
Endpoint domain: Mortality/survival
Primary endpoint: Appropriate PrEP Decision
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gait Stability Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD)
Endpoint domain: Adverse events/effects
Endpoint subdomain: Dose Limiting Toxicity (DLT)
Primary endpoint: Absence of live head lice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Diagnostic Inter-rater reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical ventilation requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Correlation of NIRs perfusion data with Doppler ultrasound perfusion parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival at one year after onset of graft versus host disease
Endpoint domain: Mortality/survival
Primary endpoint: Cancer-related fatigue evaluation
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Symptoms and Quality of Life Assessments
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time in range (70-180 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of coagulation factors deficiency in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Whole Brain 11C-PIB SUVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Subjects Seroprotected for HI Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mortality of persons suffered an accident in Alpine Mountains in Austria
Endpoint domain: Mortality/survival
Primary endpoint: Sensory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of balloonisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ETDRS best-corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of intravitreal Bevacizumab injection
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self-reported anxiety and mood symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absence of emotional disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Standard Mini Mental Test (SMMT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Retention of study participants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Right ventricular adverse remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Who Experienced Venous Thromboembolism Event [VTE]
Endpoint domain: Mortality/survival
Primary endpoint: Plasma AUC Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Etanercept levels in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Burden of health conditions affecting quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Symptom Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Target lesion size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes